Accessibility StatementSkip Navigation NEW YORK, Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the ...

In this article, we will be taking a look at the 11 Best Growth Stocks to Buy and Hold Forever.Global equities are likely to continue edging higher even as valuation concerns continue to arouse fear among investors. A survey by Bank of America of global fund managers indicates that most of them remain overweight equities. Likewise, opinions about growth have improved significantly, with only 16% of economists expecting the economy to weaken.The survey underscores the bullish thesis in the equity markets as ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 18, 2025 ...

Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DXCM usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 53 extraordinary options activities for DexCom. This level ...

Healthcare payment concept with stethoscope and big money US dollar.gettyMost Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination. They prefer linear trends—up and to the right.Dividend growers model nicely. Payout “resets” (cuts!) do not. So, there is often a knee-jerk reaction from analysts to sell every divvie slash they see.Same goes for most individual income investors. These vanilla beans sold BlackRock Health Sciences Term Trust (BMEZ) late last week w ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. DXCM, citing that the company sold the "adulterated" device.Benzinga reached out to DexCom for comments and is yet to hear from them.A surprise FDA inspection found Dexcom made an unauthorized design change to the G7 glucose monitoring device, with internal tests showing worse accuracy across the board.Despite this, the company sold the device, drawing FDA scrutiny. Executives have since departed as patient complaints climbed, rivals ...

核心观点 - 长期持有成长型股票是积累财富的有效策略 应选择具备强大经济护城河和良好增长记录的公司[1] - 推荐四只美国长期成长股：Palo Alto Networks、Ecolab、DexCom和Hubspot[1] Palo Alto Networks (PANW) - 提供AI驱动的全方位安全解决方案 涵盖网络、云和安全运营领域[2] - 2025财年收入92亿美元 同比增长15% 营业利润12亿美元 同比增长81.7%[2] - 税前利润16亿美元 同比增长61.5% 自由现金流34.7亿美元 同比增长12%[3] - 新一代安全年度经常性收入56亿美元 同比增长32%[3] - 推出两款新安全解决方案 帮助企业管理动态云和AI环境[3] - 以约250亿美元收购CyberArk Software 收购溢价26%[4] Ecolab (ECL) - 提供水处理、卫生和感染预防解决方案及服务 在170多个国家运营 员工约48,000人[5] - 2025年上半年收入77亿美元 与去年同期持平 营业利润12.7亿美元 同比增长7.7%[5] - 净利润9.267亿美元 同比增长2.6% 自由现金流6.166亿美元[6] - 宣布并支付现金股息每股0.65美元 同比增长14%[6] - 预计2025年每股收益2.02-2.12美元 同比增长10%-16%[7] DexCom (DXCM) - 医疗设备公司 生产用于糖尿病患者通过连续血糖监测仪(CGM)跟踪血糖水平的产品[8] - 2025年上半年收入22亿美元 同比增长近14% 营业利润3.463亿美元 同比增长33.7%[8] - 净利润2.852亿美元 略有下降 主要因税费大幅增加[8] - 自由现金流3.055亿美元[9] - 糖尿病患者(20-79岁成人)预计从2024年5.89亿增至2030年8.53亿[9] - 美国核心市场有450万使用胰岛素但未使用CGM的患者[9] - 在其他市场如糖尿病前期和妊娠糖尿病存在巨大机会[10] Hubspot (HUBS) - 提供云平台帮助企业发展连接和增长 包括AI互动中心、智能客户关系管理系统和连接生态系统[11] - 2025年上半年收入14.7亿美元 同比增长17.6% 毛利润12.4亿美元 同比增长16.3%[11] - 自由现金流2.598亿美元 同比增长28.7%[12] - 截至2025年6月30日客户数量267,982 同比增长18%[12] - 计算账单金额8.143亿美元 同比增长26%[12] - 总可寻址市场760亿美元 所有产品渗透率不足10% 预计2029年将增长至1,280亿美元[12]

We came across a bullish thesis on DexCom, Inc. on Flyover Stocks Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.'s share was trading at $76.22 as of September 12th. DXCM’s trailing and forward P/E were 53.68 and 29.41 respectively according to Yahoo Finance. Best Diabetes Stocks to Buy Now DexCom (DXCM) is a leading provider of continuous glucose monitoring (CGM) devices, serving millions of people managing Type 1 and Type 2 diabetes, as well as indiv ...

Market Analysis by covering: Alnylam Pharmaceuticals Inc, DexCom Inc, Veeva Systems Inc Class A, BlackRock Health Sciences Trust II. Read 's Market Analysis on Investing.com ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. Wall Street is bullish on DexCom, Inc. (NASDAQ:DXCM) after the company topped revenue and EPS estimates during its fiscal second quarter of 2025. The company posted $1.16 billion in revenue, up 15.21% year-over-year and ahead of consensus by $32.49 million. In addition, the EPS of $0.48 also came in ahead of the expectations by $0.04. Management noted that both the US and International revenue contributed to thi ...